Alkermes to Host Investor Event to Review Orexin Portfolio Strategy
Alkermes to Host Investor Event to Review Orexin Portfolio Strategy
DUBLIN, Sept. 25, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that it will host an investor event for financial analysts and institutional investors on Wednesday, Oct. 9, 2024 starting at 10:00 a.m. EDT in Waltham, Mass. Members of Alkermes' Research & Development team will review the company's orexin portfolio and development strategy. The event will also feature a clinician and thought leader panel discussion. A question and answer session will follow the presentations.
達布林,2024年9月25日/ PRNewswire/ -- 阿爾凱默斯plc(納斯達克:ALKS)宣佈,將於2024年10月9日星期三上午10:00在馬薩諸塞州沃爾瑟姆舉辦投資者活動,面向財務分析師和機構投資者。阿爾凱默斯研發團隊成員將審查公司的奧雷欣組合和發展策略。活動還將包括醫師和思想領袖小組討論。演講結束後將有問答環節。
The event will also be available virtually via webcast. Registration for the webcast is available on the Investors section of the company's website at . To ensure a timely connection, it is recommended that users register at least 15 minutes prior to the scheduled start. A replay of the webcast will be archived on the Investors section of the company's website at for 30 days following the presentation.
該活動也將通過網絡直播提供虛擬參與。用戶可以在公司網站的投資者部分註冊網絡直播。爲了確保及時連接,建議用戶至少提前15分鐘註冊。網絡直播的重播將存檔在公司網站的投資者部分,持續30天。
About Alkermes plc
Alkermes plc is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of clinical and preclinical candidates in development for neurological disorders, including narcolepsy. Headquartered in Ireland, Alkermes also has a corporate office and research and development center in Massachusetts and a manufacturing facility in Ohio. For more information, please visit Alkermes' website at .
關於阿爾凱默斯公
阿爾凱默斯是一家全球性的生物製藥公司,致力於開發神經科學領域的創新藥物。該公司擁有一系列專有的商業產品,用於治療酒精依賴、阿片類藥物依賴、精神分裂症和I型雙相情感障礙,並擁有一系列正在發展中的用於神經系統疾病,包括嗜睡病的臨床和臨床前候選藥。總部位於愛爾蘭的阿爾凱默斯還設有美國馬薩諸塞州的企業辦公室和研發中心以及俄亥俄州的製造設施。欲了解更多信息,請訪問阿爾凱默斯公司的網站.
Alkermes Contact:
Jamie Constantine
Investor Relations
+1 781 873 2402
阿爾凱默斯聯繫人:
傑米·康斯坦丁
投資者關係
+1 781 873 2402
SOURCE Alkermes plc
資料來源:阿爾凱默斯。
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
想要您公司的新聞在PRNEWSWIRE.COM上特色呈現嗎?
譯文內容由第三人軟體翻譯。